Table 2.

Prognostic factors for 78 CNS+ BL patients in Beijing Children's Hospital.

	3-year EFS	Univariable	Multivariable
Prognostic factor (n/N)	value (%)	P value	HR (95% CI)	P value
Treatment		0.002	0.567 (0.110–1.020)	0.054
R+ chemo (14/69)	76.1 ± 0.06
Chemo only (6/9)	33.3 ± 0.15
Bulky disease		0.290
Yes (10/33)	68.5 ± 0.08
No (10/45)	74.3 ± 0.07
≥4 organs involved		0.035	0.781 (0.197–2.739)	0.197
Yes (18/55)	63.9 ± 0.07
No (2/23)	91.3 ± 0.05
LDH ≥1000 U/L		0.290
Yes (13/44)	69.3 ± 0.07
No (7/34)	75.5 ± 0.08
CNP		0.430
Yes (14/48)	65.4 ± 0.09
No (6/30)	79.5 ± 0.07
CNS tumor mass		0.037	0.368 (0.366–1.548)	0.440
Negative (3/13)	75.5 ± 0.12
ICM (16/44)	59.6 ± 0.08
PME (1/21)	95.2 ± 0.04
CSF status		0.700
Negative (12/49)	72.1 ± 0.07
CSFm+ (5/14)	64.3 ± 0.12
CSFi+ (3/15)	78.6 ± 0.11

The data are presented as mean ± standard deviation, +: Positive; BL: Burkitt lymphoma; Chemo: Chemotherapy; CI: Confidence interval; CNP: Cranial nerve palsy; CNS: Central nervous system; CNS+: Central nervous system-positive; CSF: Cerebrospinal fluid; EFS: Event-free survival; HR: Hazard ratio; i: Immunophenotype; ICM: Intracerebral mass; LDH: Lactate dehydrogenase; m: Morphology; PME: Para-meningeal extension; R: Rituximab.